Nicotine replacement therapy
This article was originally published in The Tan Sheet
"Evidence-based" NRT medications should be included in "benefits provided to all federal beneficiaries and in all federally funded healthcare programs by fiscal 2005," Michael Fiore, MD, University of Wisconsin Medical School, et al. maintain in the February American Journal of Public Health. The National Action Plan for Tobacco Cessation comprises 10 recommendations to prevent "3 million premature deaths and [help] 5 mil. smokers quit." Study authors also recommend implementation of a federally funded National Tobacco Quitline to provide support for smokers who want to quit. Separately, HHS announced plans to establish and expand state quitlines in a 1Feb. 3 release. NRT marketer GlaxoSmithKline lauds the plan and "urges those in government...to implement these vital recommendations"...
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”